The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chronic Central Serous Chorioretinopathy (cCSCR)

Persistent or recurrent neurosensory retinal detachment with diffuse RPE alterations and choroidal thickening lasting > 6 months; affects working-age men and may cause permanent vision loss; key triggers are corticosteroid use and type-A personality stress.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göz Hastalıkları department. Book Appointment →

What is Chronic Central Serous Chorioretinopathy (cCSCR)?

Central serous chorioretinopathy (CSCR) is characterized by serous neurosensory retinal detachment in the macular area due to dysfunction at the level of the choroid and retinal pigment epithelium. Acute CSCR resolves spontaneously within 1–4 months in 80–90 percent of patients with good visual recovery, while chronic CSCR (cCSCR) refers to disease persisting beyond 4–6 months or with multiple recurrences leading to widespread RPE atrophy, gravitational tracks, and progressive vision loss.

Pathophysiology: choroidal hyperpermeability and thickening (pachychoroid) drive RPE dysfunction with focal or diffuse leakage of fluid into subretinal space; the underlying mechanism involves mineralocorticoid receptor (MR) overactivation in choroidal vessels (rationale for eplerenone / spironolactone treatment) and dysregulation of catecholamines and cortisol. Major risk factors: exogenous corticosteroid use (any route, even low dose — most important modifiable), endogenous hypercortisolism (Cushing syndrome, pregnancy, stress), type-A personality, sleep disturbance, Helicobacter pylori, sympathomimetic drugs, obstructive sleep apnea.

Diagnosis: OCT (subretinal fluid, RPE elevations, intraretinal cysts), fundus autofluorescence (gravitational tracts of hypoautofluorescence, hyperautofluorescent leakage points), fluorescein angiography (smokestack or inkblot leakage in acute, diffuse RPE granular hyperfluorescence and gravitational descending tracts in chronic), indocyanine green angiography (choroidal hyperpermeability and dilated choroidal vessels — pathognomonic), enhanced depth imaging OCT (increased subfoveal choroidal thickness > 300–400 µm). Differential diagnosis: polypoidal choroidal vasculopathy (PCV), CNV, vitelliform lesion, retinal pigment epithelium detachment from age-related macular degeneration.

Symptoms

Persistent central blurred vision
Central or paracentral scotoma
Metamorphopsia (distorted vision)
Micropsia (objects appear smaller)
Color desaturation
Hyperopic shift in refraction
Decreased contrast sensitivity
Recurrent episodes of vision blur and recovery (chronic course)

Risk Factors

Male sex (8:1 male predominance)
Age 30–60 years (working-age, but can be older in chronic form)
Exogenous corticosteroid use (oral, inhaled, intra-articular, topical, intranasal — strongest modifiable risk)
Endogenous hypercortisolism (Cushing syndrome)
Pregnancy
Type-A personality, psychological stress
Obstructive sleep apnea
Helicobacter pylori infection
Sympathomimetic medication use (decongestants, ADHD stimulants)
Hispanic, Asian ancestry (higher risk for chronic form and PCV)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent blurred central vision in working-age man
  • Distorted vision (Amsler grid distortion)
  • Central scotoma
  • Recurrent episodes of vision changes
  • Vision changes while on corticosteroid therapy
  • Stress-related visual symptoms
  • Known CSCR with vision worsening or new symptoms (rule out CNV)
  • Pregnancy with new visual symptoms

Treatment Methods

01
Comprehensive multimodal imaging: OCT macula, fundus autofluorescence, fluorescein angiography, indocyanine green angiography (ICG — best for choroidal vasculopathy assessment), enhanced depth imaging OCT for choroidal thickness
02
Discontinue all corticosteroids (oral, inhaled, intra-articular, intranasal, topical) in coordination with prescribing physicians; review all medications for hidden steroids
03
Lifestyle modification: stress reduction, treat obstructive sleep apnea (CPAP if present), eradicate Helicobacter pylori if positive, avoid sympathomimetics
04
First-line for persistent cCSCR with leakage: half-fluence (or half-dose) photodynamic therapy with verteporfin (gold standard, PLACE trial — superior to high-density subthreshold micropulse laser, 78 percent complete subretinal fluid resolution at 12 months)
05
Mineralocorticoid receptor antagonists: eplerenone 25–50 mg daily or spironolactone 25–50 mg daily for 1–3 months (modest effect, evidence mixed — VICI trial negative, real-world studies positive in selected patients)
06
Subthreshold micropulse laser (577 nm yellow or 810 nm diode) for extrafoveal leak points
07
Intravitreal anti-VEGF (aflibercept, ranibizumab, brolucizumab) only if choroidal neovascularization (CNV) develops (cCSCR is a major risk factor for type 1 CNV — PCV spectrum)
08
Avoid focal laser photocoagulation in modern era (creates permanent scotoma); reserved for very rare extrafoveal leak with no PDT access
09
Long-term follow-up every 3–6 months with OCT, autofluorescence; vigilance for CNV development (sudden vision change, new hemorrhage on OCT)
10
Patient education on lifelong avoidance of corticosteroid exposure where possible

Which Department to Visit?

You can visit our Göz Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göz Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.